Corona Remedies IPO Subscription Status
Corona Remedies IPO received bids for 62,65,41,440 shares against 45,71,882 offered, an overall subscription of 137.04x at the close of bidding (10 Dec 2025). QIBs lead at 278.52x.
Last updated · day 3 figures
- Retail
- 28.73x
- NII
- 208.88x
- QIB
- 278.52x
- Total
- 137.04x
Where the demand is
Corona Remedies IPO subscription by category
| Category | Shares offered | Shares bid | Amount bid | Subscription |
|---|---|---|---|---|
| QIB | 12,88,732 | 35,89,39,448 | ₹38,119.37 Cr | 278.52x |
| NII | 9,66,549 | 20,18,97,066 | ₹21,441.47 Cr | 208.88x |
| bNII above ₹10 lakh | 6,44,366 | 15,07,93,356 | ₹16,014.25 Cr | 234.02x |
| sNII ₹2–10 lakh | 3,22,183 | 5,11,03,710 | ₹5,427.21 Cr | 158.62x |
| Retail | 22,55,281 | 6,48,02,038 | ₹6,881.98 Cr | 28.73x |
| Employees | 61,320 | 9,02,888 | ₹95.89 Cr | 14.72x |
| Total | 45,71,882 | 62,65,41,440 | ₹66,538.70 Cr | 137.04x |
* Shares Offered and Total Amount are calculated based on the upper price of the issue price range. * The portion of anchor investors (or market makers) is not included in the total number of shares offered.
Corona Remedies IPO subscription day-wise
| Category | Day 3 |
|---|---|
| QIB | 278.52x |
| NII | 208.88x |
| bNII | 234.02x |
| sNII | 158.62x |
| Retail | 28.73x |
| Employees | 14.72x |
| Total | 137.04x |
| Total added | 137.04x |
Cumulative figures at the end of each day. Read across a row to see how demand built up. Shading deepens as subscription rises above 1x; "Total added" is how much overall subscription grew that day.
Corona Remedies IPO reservation
| Category | Shares | Share of issue |
|---|---|---|
| Qualified Institutional Buyers | 12,88,732 | 28.19% |
| Non-Institutional Investors | 9,66,549 | 21.14% |
| bNII · above ₹10 lakh | 6,44,366 | 67% of NII |
| sNII · ₹2–10 lakh | 3,22,183 | 33% of NII |
| Retail Individual Investors | 22,55,281 | 49.33% |
| Employee reservation | 61,320 | 1.34% |
| Public issue | 45,71,882 | 100% |
Allotment Chances Note
These are estimates from the latest application and subscription figures. Actual chances are usually somewhat better, because:
- Not every bid is at the cut-off price. Bids below the final issue price are rejected before the lottery, so fewer applications compete.
- Multiple-lot applications count once. In an oversubscribed retail or sNII portion, each application gets at most one minimum lot in the draw, however many lots it bid for.
- Invalid applications drop out. Unapproved UPI mandates, PAN mismatches and duplicate applications are removed before allotment.
Applying for more lots in the retail category does not improve your odds; applying from separate family accounts does.
Corona Remedies IPO subscription: FAQs
- What is the overall subscription of Corona Remedies IPO?
- Corona Remedies IPO is subscribed 137.04x overall as of day 3 (10 December 2025), with bids for 62,65,41,440 shares against 45,71,882 offered.
- What is the retail subscription of Corona Remedies IPO?
- The retail portion is subscribed 28.73x as of day 3 (10 December 2025).
- What is the QIB and NII subscription of Corona Remedies IPO?
- QIBs have subscribed 278.52x of their portion, and NIIs 208.88x (bNII 234.02x, sNII 158.62x) as of day 3 (10 December 2025).
- How can I check Corona Remedies IPO subscription status live?
- This page shows category-wise and day-wise figures and is updated during bidding hours. The same data is published on the BSE and NSE websites under the issue name.
- How do I apply for Corona Remedies IPO?
- Apply online through your broker or bank using UPI or ASBA. Choose the IPO, enter the number of lots and bid price (retail investors can bid at the cut-off price), and approve the UPI mandate before the issue closes on 10 December 2025.
Subscription figures are compiled from BSE and NSE bid data and can be revised by the exchanges after the issue closes. For information only; not investment advice.